Related Experiment Videos
Gene Therapy Applications to Cancer Treatment
Abstract:
Over the past ten years significant advances have been made in the fields of gene therapy and tumour immunology, such that there now exists a considerable body of evidence validating the proof in the principle of gene therapy based cancer vaccines. While clinical benefit has so far been marginal, data from preclinical and early clinical trials of gene therapy combined with standard therapies are strongly suggestive of additional benefit. Many reasons have been proposed to explain the paucity of clinical responses to single agent vaccination strategies including the poor antigenicity of tumour cells and the development of tolerance through down-regulation of MHC, costimulatory, signal transduction, and other molecules essential for the generation of strong immune responses. In addition, there is now evidence from animal models that the growing tumour may actively inhibit the host immune response. Removal of the primary tumour prior to T cell transfer from the spleen of cancer bearing animals, led to effective tumour cell line specific immunity in the recipient mouse suggesting that there is an ongoing tumour-host interaction. This model also illustrates the potential difficulties of clinical vaccine trials in patients with advanced stage disease.
Insights
Gene therapy cancer vaccines show promise, but clinical benefits are limited. Tumors can actively suppress immune responses, hindering vaccine effectiveness, especially in advanced disease.
Area of Science:
- Oncology
- Immunology
- Gene Therapy
Background:
- Significant advances in gene therapy and tumor immunology support gene therapy-based cancer vaccines.
- Preclinical and early clinical trials suggest gene therapy combined with standard treatments offers additional benefits.
- Limited clinical responses to single-agent vaccination strategies are attributed to factors like poor tumor antigenicity and immune tolerance.
Purpose of the Study:
- To review the evidence for gene therapy-based cancer vaccines.
- To explore reasons for the limited clinical efficacy of current vaccination strategies.
- To investigate the role of tumor-host interactions in immune suppression.
Main Methods:
- Review of preclinical and clinical trial data on gene therapy cancer vaccines.
- Analysis of mechanisms underlying immune evasion by tumors.
- Examination of animal models demonstrating tumor-induced immune inhibition.
Main Results:
- Gene therapy cancer vaccines demonstrate proof of principle, with marginal clinical benefit observed to date.
- Tumor cells can actively inhibit host immune responses, impacting vaccine efficacy.
- Animal models show that removing the primary tumor can enable effective anti-tumor immunity.
Conclusions:
- Gene therapy holds potential for cancer vaccines, but overcoming immune suppression is critical.
- Tumor-host interactions play a significant role in limiting the effectiveness of cancer vaccines.
- Clinical trials in advanced-stage cancer patients face challenges due to tumor-induced immune modulation.